alexa Membranous nephropathy | Argentina | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

  • 16th International Conference on Nephrology
    Nov 02-03, 2017, Atlanta, USA
Read more

Recommended Journals

Relevant Topics

Membranous Nephropathy

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Membranous nephropathy

    Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly patients between ages of 30 and 50 years, usually Caucasian. It is the second most common cause of nephrotic syndrome in adults, with focal segmental glomerulosclerosisThe incidence of minimal change disease is higher in children with a reported incidence of 2 per 100,000 per year in Caucasian children and higher rates in Arabian and Asian children".

  • Membranous nephropathy

    Disease pathophysiology: 

    Although the exact mechanisms causing pMN are still under investigation, different studies show a strong relationship between antibody levels to podocytic proteins and disease activity. Since the discovery of anti-PLA2R1 autoantibodies by Beck et al. in 2009, there has been strong evidence that they are a key player in the pathogenesis.

  • Membranous nephropathy

    Disease statistics: 

    The incidence of nephrotic syndrome is about 3 new cases per 100,000 each year in adults.In adults, diabetes mellitus is the most common secondary cause, and focal segmental glomerulosclerosis and membranous nephropathy are the most common primary causes. Minimal change disease accounts for 10%-25% of cases of nephrotic syndrome in adults.

  • Membranous nephropathy

    Disease treatment:

    Nephrotic syndrome is a relatively rare but important manifestation of kidney disease. Using the algorithm for predicting outcome described, we can rationally assign patients to conservative, nonimmunosuppressive therapy or to immunosuppressive therapy according to their risk for renal disease progression.

  • Membranous nephropathy

    Major research on disease:

    Outcomes research in glomerulonephritis.  It is present in every patient with membranous nephropathy and the process affects all glomeruli in both kidneys.  Development of proprietary assays for the identified biomarkers and assess their diagnostic and predictive values in large cohorts.

Expert PPTs

Speaker PPTs

  • Hayam I Gad
    Effects of Pravastatin or 12/15 lipoxygenase pathway inhibitors on indices of Diabetic nephropathy in an experimental model of diabetic renal disease
    PPT Version | PDF Version
 

High Impact List of Articles

Conference Proceedings

adwords